Stock Scorecard
Stock Summary for Ligand Pharmaceuticals Inc - Class B (LGND) - $317.33 as of 10/30/2026 3:09:07 PM EST
Total Score
12 out of 30
Safety Score
59 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for LGND
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for LGND
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for LGND
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for LGND
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for LGND (59 out of 100)
| Stock Price Rating (Max of 10) | 10 |
| Historical Stock Price Rating (Max of 10) | 9 |
| Stock Price Trend (Max of 10) | 10 |
| Book Value (Max of 10) | 8 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 3 |
| Trading Volume (Max of 10) | 5 |
| Price to Earnings (Max of 10) | 5 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for LGND
Financial Details for LGND
Company Overview |
|
|---|---|
| Ticker | LGND |
| Company Name | Ligand Pharmaceuticals Inc - Class B |
| Country | USA |
| Description | Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs globally. The company is headquartered in San Diego, California. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 6/30/2026 |
| Next Earnings Date | 10/29/2026 |
Stock Price History |
|
| Last Day Price | 317.33 |
| Price 4 Years Ago | 66.80 |
| Last Day Price Updated | 10/30/2026 3:09:07 PM EST |
| Last Day Volume | 299,391 |
| Average Daily Volume | 258,619 |
| 52-Week High | 326.63 |
| 52-Week Low | 175.89 |
| Last Price to 52 Week Low | 80.41% |
Valuation Measures |
|
| Trailing PE | 33.59 |
| Industry PE | 35.94 |
| Sector PE | 57.70 |
| 5-Year Average PE | 24.25 |
| Free Cash Flow Ratio | 6.28 |
| Industry Free Cash Flow Ratio | 37.15 |
| Sector Free Cash Flow Ratio | 39.66 |
| Current Ratio Most Recent Quarter | 31.18 |
| Total Cash Per Share | 50.50 |
| Book Value Per Share Most Recent Quarter | 48.57 |
| Price to Book Ratio | 6.42 |
| Industry Price to Book Ratio | 11.97 |
| Sector Price to Book Ratio | 37.05 |
| Price to Sales Ratio Twelve Trailing Months | 21.87 |
| Industry Price to Sales Ratio Twelve Trailing Months | 11.49 |
| Sector Price to Sales Ratio Twelve Trailing Months | 20.95 |
| Analyst Buy Ratings | 8 |
| Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
| Total Shares Outstanding | 19,935,600 |
| Market Capitalization | 6,326,163,948 |
| Institutional Ownership | 116.09% |
Dividends |
|
| Ex-Dividend Date | 7/2/2010 |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.4560 |
| Total Years Dividend Increasing | 0 |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | -96.96% |
| 3-Year Dividend Growth Rate Percentage | -96.96% |
| 5-Year Dividend Growth Rate Percentage | -96.96% |
| All-Time Dividend Growth Rate Percentage | -96.96% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 825.00% |
| Annual Earnings Growth | 3,186.63% |
| Reported EPS 12 Trailing Months | 9.49 |
| Reported EPS Past Year | 6.52 |
| Reported EPS Prior Year | 6.78 |
| Net Income Twelve Trailing Months | 197,220,000 |
| Net Income Past Year | 124,453,000 |
| Net Income Prior Year | -4,032,000 |
| Quarterly Revenue Growth YOY | 33.70% |
| 5-Year Revenue Growth | 10.39% |
| Operating Margin Twelve Trailing Months | 13.50% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 1,006,702,000 |
| Total Cash Past Year | 174,927,000 |
| Total Cash Prior Year | 72,307,000 |
| Net Cash Position Most Recent Quarter | -119,892,000 |
| Net Cash Position Past Year | -271,265,000 |
| Long Term Debt Past Year | 446,192,000 |
| Long Term Debt Prior Year | 76,695,000 |
| Total Debt Most Recent Quarter | 1,126,594,000 |
| Equity to Debt Ratio Past Year | 0.70 |
| Equity to Debt Ratio Most Recent Quarter | 0.46 |
| Total Stockholder Equity Past Year | 1,017,212,000 |
| Total Stockholder Equity Prior Year | 830,439,000 |
| Total Stockholder Equity Most Recent Quarter | 967,516,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 131,365,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 6.59 |
| Free Cash Flow Past Year | 48,907,000 |
| Free Cash Flow Prior Year | 77,407,000 |
Options |
|
| Put/Call Ratio | 0.70 |
| Has Options | Options Chain |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 2.09 |
| MACD Signal | 2.86 |
| 20-Day Bollinger Lower Band | 265.22 |
| 20-Day Bollinger Middle Band | 293.42 |
| 20-Day Bollinger Upper Band | 321.62 |
| Beta | 1.01 |
| RSI | 51.85 |
| 50-Day SMA | 238.51 |
| 150-Day SMA | 151.26 |
| 200-Day SMA | 130.39 |
System |
|
| Modified | 10/30/2026 3:31:23 AM EST |